MedTrace Logo

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

NCT01579578 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2014-09-12

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.

Conditions

  • Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Interventions

DRUG

AZD8931

40 mg, oral dose twice daily

DRUG

Placebo

Placebo, oral dose twice daily

DRUG

Paclitaxel

IV once weekly for 3 weeks followed by a week off.

Sponsors & Collaborators

Principal Investigators

  • Serban Ghiorghiu, M. D. · Scarborough General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Germany
  • Japan
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01579578 on ClinicalTrials.gov